Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor κB transcriptional activity

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3430-3434

  Woo, Ju Hyung ^a   Park, Jong Wook ^a   Lee, Sung Hee ^a,c   Kim, Young Ho ^a   Lee, In Kyu ^a   Gabrielson, Edward ^b   Lee, Sang Han ^a   Lee, Ho Jae ^c   Kho, Yung Hee ^c   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DYKELLIC ACID; ENZYME INHIBITOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA BINDING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B; PROLINE; PROMOTER REGIONS (GENETICS); PROPIONATES; PROTEIN STRUCTURE, TERTIARY; PYRONES; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; THIOCARBAMATES; THIOCTIC ACID; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038407256     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Stetler-Stevenson, W. G., Hewitt, R., and Corcoran, M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7: 147-154, 1996.
2. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
3. Zucker, S., Lysik, R. M., Zarrabi, M. H., and Moll, U. M(r) 92, 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53: 140-146, 1993.
4. Bemhard, E. J., Gruber, S. B., and Muschel, R. J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA, 91: 4293-4297, 1994.
5. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond.), 370: 61-65, 1994.
6. Sato, H., and Seiki, M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 8: 395-405, 1993.
7. Waas, E. T., Lomme, R. M., DeGroot, J., Wohbes, T., and Hendriks, T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer, 86: 1876-1883, 2002.
8. Lee, P. P., Hwang, J. J., Murphy, G., and Ip, M. M. Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology. 141: 3764-3773, 2000.
9. Nagase, H., and Woessner, J. F., Jr. Matrix metalloproteinases J. Biol. Chem., 274: 21491-21494, 1999.
10. Kleiner, D. E., and Stetler-Stevenson, W. G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol., 43: Suppl., S42-51, 1999.
11. Brew, K., Dinakarpandian, D., and Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 1477: 267-283, 2000.
12. Lee, H. J., Chun, H. K., Chung, M. C., Lee, C. H., Rhee, J. S., and Kho, Y. H. Biosynthesis of dykellic acid: origin of the carbon skeleton. J. Antibiot., 53: 78-80, 2000.
13. Han, S. B., Lee, H. J., Kho, Y. H., Jeon, Y. J., Lee, S. H., Kim, H. C., and Kim, H. M. New immunosuppressive activity of dykellic acid. J. Antibiot., 54: 840-843, 2001.
14. Overall, C. M., Wrana, J. L., and Sodek, J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibrolasts by transforming growth factor-β. J. Biol. Chem., 264: 1860-1869, 1989.
15. Schmitz, M. L., and Baeuerle, P. A. The p65 subunit is responsible for the strong transcription activating potential of NF-κ B. EMBO J., 10: 3805-3817, 1991.
16. Baek, W. K., Park, J. W., Lim, J. H., Suh, S. I., Suh, M. H., and Kwon, T. K. Molecular cloning and characterization of human BUB3 promoter. Gene. 295: 117-123, 2002.
17. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem., 270: 5331-5338, 1995.
18. Baldwin, A. S., Jr. The NF-κB and 1 κ B proteins: new discoveries and insights. Annu. Rev. Immunol., 14: 649-683, 1996.
19. Vanden Berghe, W., Plaisance, S., Boone, E., De Bosscher, K., Schmitz, M. L., Fiers, W., and Haegeman, G. p38 and extracellular signal-regulated kinase mitogen-acti-vated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem., 273: 3285-3290, 1998.
20. Wang, D., and Baldwin, A. S., Jr. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem., 273: 29411-29416, 1998.